VCAM1 and diabetes mellitus: Indeed, the anti-VLA-4α antibody natalizumab was previously shown to impede the interaction of pathogenic T cells with VCAM-1 on endothelial cells, and to prevent the development of EAE and diabetes in mice [48], [62].